Loring Wolcott & Coolidge Fiduciary Advisors LLP Amylyx Pharmaceuticals, Inc. Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.5 Billion
- Q2 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 1,803 shares of AMLX stock, worth $5,625. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,803
Previous 1,803
-0.0%
Holding current value
$5,625
Previous $5,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AMLX
# of Institutions
140Shares Held
44.6MCall Options Held
226KPut Options Held
909K-
Vanguard Group Inc Valley Forge, PA4.22MShares$13.2 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.34MShares$10.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$8.33 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$8.14 Million0.0% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.9MShares$5.94 Million1.57% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $183M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...